COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Expansion of Operations: CollPlant is set to enhance its North American distribution of rhCollagen and BioInk products through a new partnership with a U.S.-based logistics center, which will improve operational efficiency and support its growing customer base.
Innovative Developments: The company has made significant strides in its dermal filler program and has reported successful preclinical results, including the creation of a fully humanized bioprinted skin model, showcasing the potential of its rhCollagen technology as a non-animal alternative for medical research.
Financial Performance: CollPlant reported a notable increase in revenues for the third quarter of 2025, driven by sales of rhCollagen-based products and a milestone payment from AbbVie, while also implementing cost reduction measures that include a workforce reduction of approximately 25%.
Future Plans: The company aims to prioritize its collaboration with AbbVie and continue advancing its dermal filler product candidate, while also seeking strategic partnerships for the development of its regenerative breast implant product.
Trade with 70% Backtested Accuracy
Analyst Views on CLGN
About CLGN
About the author
CollPlant Launches BioFlex Bioink Kit for 3D Bioprinting
- BioFlex Product Launch: CollPlant has introduced the BioFlex bioink kit, based on recombinant human collagen, designed to support Digital Light Processing (DLP) 3D bioprinting, advancing drug discovery and tissue engineering.
- Technological Innovation: The BioFlex system integrates Collink.3D™ 50 biodegradable polymer and photoactive components, optimizing high-resolution printing and significantly enhancing the mechanical properties and structural integrity of bioinks.
- Market Applications: This product is suitable for both academic laboratories and industrial R&D, facilitating faster translation in 3D bioprinting and regenerative medicine, thereby shortening product development cycles.
- Strategic Importance: CollPlant CEO Yehiel Tal stated that BioFlex will streamline the formulation process, reduce development costs, and provide an animal-free high-resolution printing solution, supporting innovation in biopharma and academic research.
CollPlant Launches BioFlex Bioink for Advanced 3D Bioprinting
- BioFlex Product Launch: CollPlant has introduced the BioFlex bioink kit, specifically designed for Digital Light Processing (DLP) 3D bioprinting applications, aimed at supporting biofabrication for drug discovery and engineered tissues, marking a significant technological advancement in regenerative medicine.
- High-Performance Features: The BioFlex system integrates Collink.3D™ 50 biodegradable polymer with optimized photoactive components, enabling users to efficiently generate bioinks with tunable mechanical properties, thereby facilitating the precise fabrication of complex biological structures and enhancing applications in tissue engineering.
- Reduced Development Time: By streamlining the formulation development process, BioFlex significantly shortens R&D timelines, allowing researchers and industry partners to quickly achieve high-resolution printing outcomes, thus promoting faster translation from concept to functional tissue constructs.
- Market Competitive Advantage: As an animal-free alternative, BioFlex offers high-resolution, scalable, and highly reproducible bioprinting solutions, helping CollPlant secure a leading position in the fields of regenerative medicine and tissue engineering while reducing overall development costs and accelerating innovation timelines.
Wall Street Analysts Adjust Ratings on Top Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market views and expectations for these companies.
- Market Reaction: While specific stocks were not mentioned, such rating changes typically influence investor decisions and may lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying PI stock should pay attention to analysts' opinions to better assess potential investment risks and returns.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, especially in a rapidly changing market environment.
D. Boral Capital Upholds Buy Rating for CollPlant Biotechnologies (CLGN)
Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for CollPlant Biotechnologies, with a projected one-year price target of $11.73/share, indicating a potential upside of 436.16% from its current price of $2.19/share.
Projected Revenue and EPS: CollPlant Biotechnologies is expected to see a significant increase in annual revenue, projected at $5,277 million, alongside a non-GAAP EPS forecast of 6.62.
Fund Sentiment: There has been a slight increase in institutional ownership, with 17 funds reporting positions in CollPlant, although total shares owned by institutions decreased by 19.63% over the last three months.
Shareholder Activity: Notable shareholders like Villere St Denis J & Co and AMH Equity have increased their holdings in CollPlant, while Renaissance Technologies has significantly reduced its stake.
D. Boral Capital Reiterates Buy Rating for CollPlant Biotechnologies with $12 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
CollPlant Partners with U.S. Logistics Center to Expand North American Market
- Market Expansion: CollPlant has established a partnership with a U.S.-based logistics center expected to become operational this quarter, aimed at enhancing distribution capabilities for its rhCollagen and BioInk products across the U.S. and Canada, thereby supporting its growing customer base.
- Innovation Breakthrough: CollPlant's rhCollagen has been utilized in research at Mayo Clinic to develop the first fully humanized 3D bioprinted skin model, providing a sustainable alternative to animal testing, showcasing its broad application potential in medical and aesthetic fields.
- Financial Improvement: CollPlant reported GAAP revenues of $77,000 for the third quarter, a significant increase from $4,000 in the same period last year, primarily driven by increased sales of rhCollagen products, indicating a gradual recovery in the market.
- Cost Control: CollPlant has implemented a cost reduction plan expected to reduce its workforce by approximately 25%, aimed at optimizing resource allocation and extending its cash runway to support future R&D and market expansion.
CollPlant Launches BioFlex Bioink Kit for 3D Bioprinting
- BioFlex Product Launch: CollPlant has introduced the BioFlex bioink kit, based on recombinant human collagen, designed to support Digital Light Processing (DLP) 3D bioprinting, advancing drug discovery and tissue engineering.
- Technological Innovation: The BioFlex system integrates Collink.3D™ 50 biodegradable polymer and photoactive components, optimizing high-resolution printing and significantly enhancing the mechanical properties and structural integrity of bioinks.
- Market Applications: This product is suitable for both academic laboratories and industrial R&D, facilitating faster translation in 3D bioprinting and regenerative medicine, thereby shortening product development cycles.
- Strategic Importance: CollPlant CEO Yehiel Tal stated that BioFlex will streamline the formulation process, reduce development costs, and provide an animal-free high-resolution printing solution, supporting innovation in biopharma and academic research.
CollPlant Launches BioFlex Bioink for Advanced 3D Bioprinting
- BioFlex Product Launch: CollPlant has introduced the BioFlex bioink kit, specifically designed for Digital Light Processing (DLP) 3D bioprinting applications, aimed at supporting biofabrication for drug discovery and engineered tissues, marking a significant technological advancement in regenerative medicine.
- High-Performance Features: The BioFlex system integrates Collink.3D™ 50 biodegradable polymer with optimized photoactive components, enabling users to efficiently generate bioinks with tunable mechanical properties, thereby facilitating the precise fabrication of complex biological structures and enhancing applications in tissue engineering.
- Reduced Development Time: By streamlining the formulation development process, BioFlex significantly shortens R&D timelines, allowing researchers and industry partners to quickly achieve high-resolution printing outcomes, thus promoting faster translation from concept to functional tissue constructs.
- Market Competitive Advantage: As an animal-free alternative, BioFlex offers high-resolution, scalable, and highly reproducible bioprinting solutions, helping CollPlant secure a leading position in the fields of regenerative medicine and tissue engineering while reducing overall development costs and accelerating innovation timelines.
Wall Street Analysts Adjust Ratings on Top Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market views and expectations for these companies.
- Market Reaction: While specific stocks were not mentioned, such rating changes typically influence investor decisions and may lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying PI stock should pay attention to analysts' opinions to better assess potential investment risks and returns.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, especially in a rapidly changing market environment.
D. Boral Capital Upholds Buy Rating for CollPlant Biotechnologies (CLGN)
Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for CollPlant Biotechnologies, with a projected one-year price target of $11.73/share, indicating a potential upside of 436.16% from its current price of $2.19/share.
Projected Revenue and EPS: CollPlant Biotechnologies is expected to see a significant increase in annual revenue, projected at $5,277 million, alongside a non-GAAP EPS forecast of 6.62.
Fund Sentiment: There has been a slight increase in institutional ownership, with 17 funds reporting positions in CollPlant, although total shares owned by institutions decreased by 19.63% over the last three months.
Shareholder Activity: Notable shareholders like Villere St Denis J & Co and AMH Equity have increased their holdings in CollPlant, while Renaissance Technologies has significantly reduced its stake.
D. Boral Capital Reiterates Buy Rating for CollPlant Biotechnologies with $12 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
CollPlant Partners with U.S. Logistics Center to Expand North American Market
- Market Expansion: CollPlant has established a partnership with a U.S.-based logistics center expected to become operational this quarter, aimed at enhancing distribution capabilities for its rhCollagen and BioInk products across the U.S. and Canada, thereby supporting its growing customer base.
- Innovation Breakthrough: CollPlant's rhCollagen has been utilized in research at Mayo Clinic to develop the first fully humanized 3D bioprinted skin model, providing a sustainable alternative to animal testing, showcasing its broad application potential in medical and aesthetic fields.
- Financial Improvement: CollPlant reported GAAP revenues of $77,000 for the third quarter, a significant increase from $4,000 in the same period last year, primarily driven by increased sales of rhCollagen products, indicating a gradual recovery in the market.
- Cost Control: CollPlant has implemented a cost reduction plan expected to reduce its workforce by approximately 25%, aimed at optimizing resource allocation and extending its cash runway to support future R&D and market expansion.
